Published in Eur Urol on January 09, 2014
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med (2016) 4.31
The prostate health index selectively identifies clinically significant prostate cancer. J Urol (2014) 2.68
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol (2015) 2.29
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol (2016) 1.48
Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. J Natl Cancer Inst (2015) 1.42
Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort. PLoS One (2017) 1.38
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer (2015) 0.98
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer (2014) 0.98
The changing incidence of thyroid cancer. Nat Rev Endocrinol (2016) 0.96
Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis (2015) 0.93
First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics (2015) 0.92
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol (2015) 0.91
The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol (2015) 0.89
Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol (2014) 0.87
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology (2016) 0.86
MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol (2015) 0.84
MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. Biomed Res Int (2014) 0.83
The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study. Asian J Androl (2016) 0.83
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer (2015) 0.82
Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. World J Urol (2016) 0.82
Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis. PLoS One (2015) 0.81
Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial. BJU Int (2016) 0.81
Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res (2016) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Serum markers in prostate cancer detection. Curr Opin Urol (2015) 0.80
Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study. World J Urol (2016) 0.80
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology (2016) 0.79
Personalized prostate cancer care: from screening to treatment. Asian J Androl (2016) 0.79
The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urol Clin North Am (2016) 0.79
Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. PLoS One (2015) 0.79
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst (2017) 0.78
Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer. Oncotarget (2016) 0.78
The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer. J Urol (2015) 0.78
Changing the Paradigm of Cancer Screening, Prevention, and Treatment. Dose Response (2016) 0.78
Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers. Future Oncol (2016) 0.78
Prostate imaging--the future is now: current concepts and future potentials. World J Urol (2014) 0.77
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clin Epigenetics (2016) 0.77
Will Multi-Parametric Magnetic Resonance Imaging be the Future Tool to Detect Clinically Significant Prostate Cancer? Front Oncol (2014) 0.77
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clin Cancer Res (2016) 0.77
Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging (2016) 0.76
Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol (2016) 0.76
Ethnicity and prostate cancer: the way to solve the screening problem? BMC Med (2015) 0.76
The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol (2015) 0.76
Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. Ecancermedicalscience (2016) 0.75
Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort. J Korean Med Sci (2016) 0.75
Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics (2016) 0.75
Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. Sci Rep (2017) 0.75
The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message? Eur Urol (2014) 0.75
Appraising the European randomized study of screening for prostate cancer: what do the results mean? Asian J Androl (2015) 0.75
Can nomograms improve our ability to select candidates for active surveillance for prostate cancer? Prostate Cancer Prostatic Dis (2016) 0.75
The Treatment of Localized Prostate Cancer in Everyday Practice in Germany. Dtsch Arztebl Int (2016) 0.75
Prostate cancer detection using multiparametric 3 - tesla MRI and fusion biopsy: preliminary results. Int Braz J Urol (2016) 0.75
Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Curr Opin Urol (2017) 0.75
Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer. Eur Urol (2015) 0.75
The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis (2017) 0.75
Emotional Distress Increases the Likelihood of Undergoing Surgery among Men with Localized Prostate Cancer. J Urol (2016) 0.75
Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies. Prostate Cancer (2016) 0.75
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. PLoS One (2015) 0.75
Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis (2017) 0.75
The context of prostate cancer genomics in personalized medicine. Oncol Lett (2017) 0.75
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. Int J Mol Sci (2017) 0.75
Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence. Cancer Res (2017) 0.75
[Multiparametric MRI of the prostate : Important radiological findings for urologists]. Radiologe (2017) 0.75
Elevated hardness of peripheral gland on real-time elastography is an independent marker for high-risk prostate cancers. Radiol Med (2017) 0.75
Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging. World J Urol (2016) 0.75
Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy. World J Urol (2016) 0.75
Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiology (2017) 0.75
Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol (2017) 0.75
Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol (2016) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Overdiagnosis in cancer. J Natl Cancer Inst (2010) 10.31
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int (2012) 4.01
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol (2007) 3.49
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (1995) 3.25
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer (2010) 2.61
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen (2012) 2.21
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol (2005) 2.00
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med (2013) 1.84
Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology (2010) 1.83
Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev (2011) 1.77
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol (2013) 1.74
Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate (2003) 1.73
Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology (2011) 1.70
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int (2012) 1.68
Under diagnosis and over diagnosis of prostate cancer. J Urol (2007) 1.61
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer (2009) 1.59
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
There is more to life than death. N Engl J Med (2012) 1.43
Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer (2008) 1.39
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol (2011) 1.28
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol (2007) 1.18
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13
Overdiagnosis in early detection programs. Biostatistics (2004) 1.12
Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. Prostate (2005) 1.08
Stage migration in clinically localized prostate cancer. Eur Urol (2000) 1.04
Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst (2013) 1.01
Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL. BJU Int (2008) 1.00
Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? J Urol (2004) 0.98
Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int (2011) 0.98
A note on the catch-up time method for estimating lead or sojourn time in prostate cancer screening. Stat Med (2013) 0.97
The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. Prostate Cancer Prostatic Dis (2011) 0.93
Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer (2013) 0.92
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol (2009) 0.92
Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study. Prostate Cancer Prostatic Dis (2006) 0.92
Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. Am J Clin Oncol (2013) 0.91
Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int (2008) 0.87
Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. J Urol (2007) 0.84
Retracted Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int (2013) 0.82
Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies. Asian J Androl (2012) 0.81
Results of the three rounds of the Finnish Prostate Cancer Screening Trial--the incidence of advanced cancer is decreased by screening. Int J Cancer (2010) 0.81
Systematic review of complications of prostate biopsy. Eur Urol (2013) 3.66
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol (2014) 1.42
Social media offers unprecedented opportunities for vibrant exchange of professional ideas across continents. Eur Urol (2014) 0.86